Coverage: LD-2 reports for 2025 onward, posted Jan 1, 2025 through Oct 28, 2026. Only the current version of each report is used.
67,060 report citations, newest first.
POWER & COMMUNICATION CONTRACTORS ASSOCIATION · lobbying firm or registrant: GOVERNMENT AFFAIRS SOLUTIONS, LLC
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 21, 2026 · issue area: Telecommunications
$50,000
Paid to lobbying firm
CitesH.R. 3898· this member:Recorded votes on 2 roll calls
…editing Economic Development Act (SPEED Act) (H.R. 4776) Support for provisions of the Promoting Efficient Review for Modern Infrastructure for Today (PERMIT) (H.R. 3898) Support for the Studying NEPAs Impact on Projects Act (H.R. 573), which requires the Council on Environmental Quality (CEQ) to publish an annual report on NEP…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
POWER & COMMUNICATION CONTRACTORS ASSOCIATION · lobbying firm or registrant: GOVERNMENT AFFAIRS SOLUTIONS, LLC
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 21, 2026 · issue area: Telecommunications
$50,000
Paid to lobbying firm
CitesH.R. 4776· this member:Recorded votes on 5 roll calls
…fiber broadband funding and programs, in general. Permit Reform: Support for the Standardizing Permitting and Expediting Economic Development Act (SPEED Act) (H.R. 4776) Support for provisions of the Promoting Efficient Review for Modern Infrastructure for Today (PERMIT) (H.R. 3898) Support for the Studying NEPAs Impact on Pro…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
POWER & COMMUNICATION CONTRACTORS ASSOCIATION · lobbying firm or registrant: GOVERNMENT AFFAIRS SOLUTIONS, LLC
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 21, 2026 · issue area: Labor Issues/Antitrust/Workplace
$50,000
Paid to lobbying firm
CitesH.R. 4896· this member:Cosponsored
…rge petition in the House. Opposition to Protecting the Right to Organize (PRO) Act (H.R. 20/S. 852). Opposition to the Warehouse Worker Protection Act (S.2613/H.R.4896.) Support for Senate HELP Committee legislative labor reforms, in general. Support for the Employee Rights Act (H.R. 4154/S. 2984). Support for the Start Apply…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
POWER & COMMUNICATION CONTRACTORS ASSOCIATION · lobbying firm or registrant: GOVERNMENT AFFAIRS SOLUTIONS, LLC
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 21, 2026 · issue area: Immigration
$50,000
Paid to lobbying firm
CitesH.R. 4393· this member:Cosponsored
The Dignity Act (H.R. 4393) Essential Workers for Economic Advancement Act (H.R. 3734) Engagement on VISA, DACA, TPS, and other legal immigration programs salient to construction industr…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
POWER & COMMUNICATION CONTRACTORS ASSOCIATION · lobbying firm or registrant: GOVERNMENT AFFAIRS SOLUTIONS, LLC
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 21, 2026 · issue area: Government Issues
$50,000
Paid to lobbying firm
CitesH.R. 425· this member:Cosponsored
Support for the Prove it Act of 2025 (H.R. 425/S. 100). Education about and comments regarding OMB Proposed Rule, Regulation for Federal Financial Assistance (91 FR 32198, Docket No. OMB-2026-0034)
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN ASSOCIATION OF NURSE ANESTHETISTS · lobbying firm or registrant: AMERICAN ASSOCIATION OF NURSE ANESTHETISTS
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 21, 2026 · issue area: Education
$240,000
Spent on own lobbying
CitesH.R. 3593· this member:Cosponsored
Title VIII Nursing Workforce Reauthorization Act of 2025 (H.R. 3593/ S. 1847) - Issues pertaining to the reauthorization of the Title VIII program Title VIII Funding for Fiscal Year 2026 and Fiscal Year 2027 Nursing is a Profes…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN ASSOCIATION OF NURSE ANESTHETISTS · lobbying firm or registrant: AMERICAN ASSOCIATION OF NURSE ANESTHETISTS
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 21, 2026 · issue area: Education
$240,000
Spent on own lobbying
CitesH.R. 6718· this member:Sponsored
…ear 2027 Nursing is a Professional Degree Act (S.4568/H.R.8691) - Issues pertaining to graduate student loan limits for APRNs. Professional Student Degree Act (H.R. 6718) - Issues pertaining to graduate student loan limits for APRNs.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
BIOTECHNOLOGY INNOVATION ORGANIZATION · lobbying firm or registrant: BIOTECHNOLOGY INNOVATION ORGANIZATION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 21, 2026 · issue area: Health Issues
$2,560,000
Spent on own lobbying
CitesH.R. 1672· this member:Cosponsored
…Act ---S.1954: Biosimilar Red Tape Elimination Act ---Biosimilars Competition (General) ---Interchangeability and Pharmacy Substitution Cell & Gene Therapy ---H.R.1672: Maintaining Investments in New Innovation (MINI) Act Clinical Trial Data in China ---Next-Generation U.S. Clinical Development to Accelerate Cures - Legislati…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
BIOTECHNOLOGY INNOVATION ORGANIZATION · lobbying firm or registrant: BIOTECHNOLOGY INNOVATION ORGANIZATION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 21, 2026 · issue area: Health Issues
$2,560,000
Spent on own lobbying
CitesH.R. 3521· this member:Cosponsored
…Act ---Clinical Trial Data in China ---Implementation of BIOSECURE Act Diagnostics and Personalized Medicine Regulation and Oversight Diversity & Inclusion ---H.R.3521: Clinical Trial Modernization Act ---Decentralized Clinical Trials Drug Evaluation and Review ---S.43/H.R.6485: Skinny Labels, Big Savings Act ---FDA Hiring Fl…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
BIOTECHNOLOGY INNOVATION ORGANIZATION · lobbying firm or registrant: BIOTECHNOLOGY INNOVATION ORGANIZATION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 21, 2026 · issue area: Health Issues
$2,560,000
Spent on own lobbying
CitesH.R. 5509· this member:Cosponsored
…-H.R.10359: Priority for Pediatric Cures Act ---S.822: Scientific EXPERT Act ---Rare Disease Pilot Program Reimbursement and Coverage of Innovative Products ---H.R.5509/S.2903:SAFE STEP Act ---S.864/H.R.6423: HELP Copays Act ---Access to Innovative Treatments ---CMMI Authority ---Implementation of the Inflation Reduction Act (…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
BIOTECHNOLOGY INNOVATION ORGANIZATION · lobbying firm or registrant: BIOTECHNOLOGY INNOVATION ORGANIZATION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 21, 2026 · issue area: Health Issues
$2,560,000
Spent on own lobbying
CitesH.R. 8800· this member:Recorded votes on 21 roll calls
…sign ---Most Favored Nation Drug Pricing Proposals ---Pricing and Rebates National Defense ---Medical Countermeasure Priority Review Voucher Reauthorization ---H.R.8800: National Defense Authorization Act for Fiscal Year 2027 National Security ---H.R.10568: Protecting Biological Data as Critical Infrastructure Act ---H.R.10569…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
BIOTECHNOLOGY INNOVATION ORGANIZATION · lobbying firm or registrant: BIOTECHNOLOGY INNOVATION ORGANIZATION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 21, 2026 · issue area: Homeland Security
$2,560,000
Spent on own lobbying
CitesH.R. 8800· this member:Recorded votes on 21 roll calls
…rug User Fee Act (PDUFA) VIII Implementation ---VICP/CICP Biodefense Research, Development and Procurement Issues ---H.R.1980: State Strategic Stockpile Act ---H.R.8800: National Defense Authorization Act for Fiscal Year 2027 ---Ebola BDBV Outbreak ---Hanta Virus ---Medical Countermeasure Priority Review Voucher Reauthorizatio…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
BIOTECHNOLOGY INNOVATION ORGANIZATION · lobbying firm or registrant: BIOTECHNOLOGY INNOVATION ORGANIZATION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 21, 2026 · issue area: Medicare/Medicaid
$2,560,000
Spent on own lobbying
CitesH.R. 1414· this member:Cosponsored
…--Most Favored Nation in Medicaid ---Pricing and Rebates ---Value-Based Purchasing (VBP) Rule Opioid Crisis ---Coverage and Reimbursement Orphan Drug Issues ---H.R.1414: Cameron's Law ---H.R.6166: Lowering Drug Costs for American Families Act ---H.R.10359: Priority for Pediatric Cures Act ---Implementation of the Inflation Red…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
BIOTECHNOLOGY INNOVATION ORGANIZATION · lobbying firm or registrant: BIOTECHNOLOGY INNOVATION ORGANIZATION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 21, 2026 · issue area: Medicare/Medicaid
$2,560,000
Spent on own lobbying
CitesH.R. 1672· this member:Cosponsored
…Biosimilars Access and Affordability Act ---S.1954: Biosimilars Red Tape Elimination Act ---Interchangeability and Pharmacy Substitution Cell & Gene Therapy ---H.R.1672: Maintaining Investments and New Innovation (MINI) Act ---H.R.7871/S.1637: MVP Act Clinical Trial Data in China Data Privacy ---H.R.8413: SECURE Data Act Diver…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
BIOTECHNOLOGY INNOVATION ORGANIZATION · lobbying firm or registrant: BIOTECHNOLOGY INNOVATION ORGANIZATION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 21, 2026 · issue area: Small Business
$2,560,000
Spent on own lobbying
CitesH.R. 3339· this member:Cosponsored
Banking Policy Impacting Emerging Companies ---Regulatory Burden Capital Formation Incentives ---H.R.3323: Helping Startups Continue To Grow Act ---H.R.3339: Equal Opportunity for All Investors Act of 2025 ---H.R.3348: Accredited Investor Definition Review Act ---H.R.3382/S.2924: Small Entity Update Act ---H.R.3394…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
BIOTECHNOLOGY INNOVATION ORGANIZATION · lobbying firm or registrant: BIOTECHNOLOGY INNOVATION ORGANIZATION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 21, 2026 · issue area: Small Business
$2,560,000
Spent on own lobbying
CitesH.R. 3382· this member:Cosponsored
…3: Helping Startups Continue To Grow Act ---H.R.3339: Equal Opportunity for All Investors Act of 2025 ---H.R.3348: Accredited Investor Definition Review Act ---H.R.3382/S.2924: Small Entity Update Act ---H.R.3394: Fair Investment Opportunities for Professional Experts Act ---H.R.4430: Expanding WKSI Eligibility Act Capital Mar…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
BIOTECHNOLOGY INNOVATION ORGANIZATION · lobbying firm or registrant: BIOTECHNOLOGY INNOVATION ORGANIZATION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 21, 2026 · issue area: Small Business
$2,560,000
Spent on own lobbying
CitesH.R. 3394· this member:Recorded vote on 1 roll call
…H.R.3339: Equal Opportunity for All Investors Act of 2025 ---H.R.3348: Accredited Investor Definition Review Act ---H.R.3382/S.2924: Small Entity Update Act ---H.R.3394: Fair Investment Opportunities for Professional Experts Act ---H.R.4430: Expanding WKSI Eligibility Act Capital Market Enhancements ---Accredited Investor Defi…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
BIOTECHNOLOGY INNOVATION ORGANIZATION · lobbying firm or registrant: BIOTECHNOLOGY INNOVATION ORGANIZATION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 21, 2026 · issue area: Taxation/Internal Revenue Code
$2,560,000
Spent on own lobbying
CitesH.R. 1· this member:Recorded votes on 3 roll calls
…Orphan Drug Issues ---H.R.1414: Cameron's Law ---H.R.10359: Priority for Pediatric Cures Act Pandemic Preparedness Research & Development Tax Credit Reforms ---H.R.1: One Big Beautiful Bill Act ---H.R.1414: Cameron's Law ---Expensing of R&D Expenditures Vaccines and Infectious Disease ---H.R.9672: Vaccine Injury Compensatio…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
BIOTECHNOLOGY INNOVATION ORGANIZATION · lobbying firm or registrant: BIOTECHNOLOGY INNOVATION ORGANIZATION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 21, 2026 · issue area: Taxation/Internal Revenue Code
$2,560,000
Spent on own lobbying
CitesH.R. 1414· this member:Cosponsored
…s for Specific Issues ---Vaccines and Infectious Diseases ---VICP/CICP Capital Formation Incentives ---Net Operating Loss Advance Refunds Orphan Drug Issues ---H.R.1414: Cameron's Law ---H.R.10359: Priority for Pediatric Cures Act Pandemic Preparedness Research & Development Tax Credit Reforms ---H.R.1: One Big Beautiful Bill…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
NATIONAL TOUR ASSOCIATION · lobbying firm or registrant: ELEVATE GOVERNMENT AFFAIRS, LLC
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 21, 2026 · issue area: Real Estate/Land Use/Conservation
$10,000
Paid to lobbying firm
CitesH.R. 9250· this member:Cosponsored
…The One Big Beautiful Bill Act (P.L. 119-21). Issues related to the America the Beautiful Act (S.1547), Issues related to the Great American Outdoors Act 250 (H.R.9250).
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
WEST HARLEM ENVIRONMENTAL ACTION, INC. · lobbying firm or registrant: WEST HARLEM ENVIRONMENTAL ACTION, INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 21, 2026 · issue area: Environment/Superfund
$30,000
Spent on own lobbying
CitesH.R. 4776· this member:Recorded votes on 5 roll calls
…onitoring regarding: -Environmental Justice, including the reintroduction of the Environmental Justice for All Act, a Energy Bill of Rights, and Data centers; -H.R.4776 - SPEED Act; -H.R.6782 - Public Health Air Quality Act of 2025; -S.2675/H.R.5104 - HEAT Illness & Deaths Act; -NEPA and permitting issues.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
LINCOLN NATIONAL CORPORATION · lobbying firm or registrant: LINCOLN NATIONAL CORPORATION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 21, 2026 · issue area: Taxation/Internal Revenue Code
$240,000
Spent on own lobbying
CitesH.R. 1· this member:Recorded votes on 3 roll calls
HR 1 / PL 119-21 One Big Beautiful Bill Act. HR 2547/S 1335 Secure Family Futures Act. Issue: debt investment tax change from capital to ordinary. Public Law 117-16…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
LINCOLN NATIONAL CORPORATION · lobbying firm or registrant: LINCOLN NATIONAL CORPORATION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 21, 2026 · issue area: Taxation/Internal Revenue Code
$240,000
Spent on own lobbying
CitesH.R. 2547· this member:Cosponsored
HR 1 / PL 119-21 One Big Beautiful Bill Act. HR 2547/S 1335 Secure Family Futures Act. Issue: debt investment tax change from capital to ordinary. Public Law 117-169. Issue: implementation of corporate minimum ta…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
LINCOLN NATIONAL CORPORATION · lobbying firm or registrant: LINCOLN NATIONAL CORPORATION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 21, 2026 · issue area: Retirement
$240,000
Spent on own lobbying
CitesH.R. 1013· this member:Cosponsored
Public Law 117-328 Consolidated Appropriations Act of 2023. Issue: SECURE 2.0 implementation. HR 1013/S 424 Fairness for Charities and Educational Institutions Act of 2025. Issue: expansion of investment options for 403(b) plans. HR 6084 ERISA Litigation Reform…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ALLIANZ · lobbying firm or registrant: VENN STRATEGIES
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 21, 2026 · issue area: Taxation/Internal Revenue Code
$50,000
Paid to lobbying firm
CitesH.R. 2547· this member:Cosponsored
International tax issues, including retaliatory taxes and administrative guidance from the OECD regarding Pillar II. S.1335/H.R.2547, the Secure Family Futures Act of 2025.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
